TreeFrog’s TFG-001 Shows Strong Parkinson’s Recovery Data
BORDEAUX, France, May 25, 2026 TreeFrog Therapeutics announced new preclinical data showing that its investigational 3D neural microtissue cell...
IPSC
Advertisement
Pluristyx and Qkine Sign Strategic iPSC Distribution Deal
SEATTLE, Washington & CAMBRIDGE, UK, May 1, 2026 Pluristyx and Qkine announced a reciprocal distribution agreement aimed at streamlining...
Century Therapeutics Highlights CNTY-813 Data at ADA
PHILADELPHIA, Pennsylvania, April 2026 Century Therapeutics announced that its investigational program CNTY-813 has been selected for oral presentation at...
Fate Therapeutics FT839 CAR T Shows Strong Preclinical Data
SAN DIEGO, Calif., April 16, 2026 Fate Therapeutics, Inc. has announced the presentation of preclinical data for its next-generation...
XellSmart Advances Phase 2 Parkinson’s Cell Therapy Trial
Suzhou, China | April 14, 2026 XellSmart has announced the initiation of a multicenter Phase II clinical trial evaluating...
Advertisements
Aspen Neuroscience Secures $115M to Advance Cell Therapy
SAN DIEGO, CA — November 20, 2025 — Aspen Neuroscience, a leading developer of personalized autologous cell therapies for...
Aspen Advances Parkinson’s Therapy with Commercial ANPD001 Formulation
SAN DIEGO, Sept. 25, 2025 (cGxP.wire) – Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, announced...
Advertisement
